Order Article Reprints

Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, et al. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine. 2019; 8(12):2180. https://doi.org/10.3390/jcm8122180

Lopez-Bonet, Eugeni, Maria Buxó, Elisabet Cuyàs, Sonia Pernas, Joan Dorca, Isabel Álvarez, Susana Martínez, Jose Manuel Pérez-Garcia, Norberto Batista-López, César A. Rodríguez-Sánchez, and et al. 2019. "Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer" Journal of Clinical Medicine 8, no. 12: 2180. https://doi.org/10.3390/jcm8122180

Lopez-Bonet, E., Buxó, M., Cuyàs, E., Pernas, S., Dorca, J., Álvarez, I., Martínez, S., Pérez-Garcia, J. M., Batista-López, N., Rodríguez-Sánchez, C. A., Amillano, K., Domínguez, S., Luque, M., Morilla, I., Stradella, A., Viñas, G., Cortés, J., Oliveras, G., Meléndez, C., ... Menendez, J. A. (2019). Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine, 8(12), 2180. https://doi.org/10.3390/jcm8122180